Table 1.
Comparison of clinicopathological variables by androgen receptor status.
| Variable | Level | All (149) | Negative AR (94, 63.3%) | Positive AR (55, 36.7%) | P* | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||
| Age | Mean | 49.05 | 47.88 | 51.07 | 0.412 | |||
| Median | 49 | 47 | 51.5 | |||||
| SD | 12.75323 | 13.33413 | 11.3984 | |||||
| BMI | Mean | 30.84 | 30.39 | 31.6 | 0.272 | |||
| Median | 30 | 30 | 31 | |||||
| SD | 6.533152 | 6.675402 | 6.204601 | |||||
| Menopause Status | Postmenopausal | 70 | 46.98% | 40 | 42.55% | 30 | 54.55% | 0.157 |
| Premenopausal | 79 | 53.02% | 54 | 57.45% | 25 | 45.45% | ||
| Comorbidities | Yes | 61 | 40.94% | 43 | 45.74% | 18 | 32.73% | 0.119 |
| No | 88 | 59.06% | 51 | 54.26% | 37 | 67.27% | ||
| Family History of breast cancer | Yes | 51 | 34.23% | 28 | 29.79% | 23 | 41.82% | 0.51 |
| No | 98 | 65.77% | 66 | 70.21% | 32 | 58.18% | ||
| Clinical Stage | Ia | 15 | 10.07% | 10 | 10.64% | 5 | 9.09% | 0.412 |
| IIa | 45 | 30.20% | 27 | 28.72% | 18 | 32.73% | ||
| IIb | 47 | 31.54% | 29 | 30.85% | 18 | 32.73% | ||
| IIIa | 32 | 21.48% | 20 | 21.28% | 12 | 21.82% | ||
| IIIb | 7 | 4.70% | 7 | 7.45% | 0 | 0.00% | ||
| IIIc | 3 | 2.01% | 1 | 1.06% | 2 | 3.64% | ||
| Grade | I | 2 | 1.34% | 0 | 0.00% | 2 | 3.64% | 0.224 |
| II | 28 | 18.79% | 20 | 21.28% | 8 | 14.55% | ||
| III | 112 | 75.17% | 70 | 74.47% | 42 | 76.36% | ||
| NA | 7 | 4.70% | 4 | 4.26% | 3 | 5.45% | ||
| Clinical T Stage | T1 | 21 | 14.09% | 14 | 14.89% | 7 | 12.73% | 0.156 |
| T2 | 78 | 52.35% | 47 | 50.00% | 31 | 56.36% | ||
| T3 | 43 | 28.86% | 26 | 27.66% | 17 | 30.91% | ||
| T4 | 7 | 4.70% | 7 | 7.45% | 0 | 0.00% | ||
| Clinical N Stage | N0 | 71 | 47.65% | 45 | 47.87% | 26 | 47.27% | 0.679 |
| N1 | 63 | 42.28% | 41 | 43.62% | 22 | 40.00% | ||
| N2 & N3 | 15 | 10.07% | 8 | 8.51% | 7 | 12.73% | ||
| Neoadjuvant CTx | No | 66 | 44.30% | 43 | 45.74% | 23 | 41.82% | 0.585 |
| Yes | 83 | 55.70% | 51 | 54.26% | 32 | 58.18% | ||
| Neoadjuvant Chemotherapy (CTX) regimen | AC + Taxotere | 71 | 85.54% | 45 | 88.24% | 26 | 81.25% | 0.553 |
| AC | 1 | 1.20% | 0 | 0.00% | 1 | 3.13% | ||
| Cyclophosphamide + Doxorubicin | 2 | 2.41% | 1 | 1.96% | 1 | 3.13% | ||
| FEC + Paclitaxel | 1 | 1.20% | 1 | 1.96% | 0 | 0.00% | ||
| Taxol | 1 | 1.20% | 1 | 1.96% | 0 | 0.00% | ||
| NA | 7 | 8.43% | 3 | 5.88% | 4 | 12.50% | ||
| Clinical Response post Neoadjuvant | Complete | 4 | 4.82% | 3 | 5.88% | 1 | 3.13% | 0.936 |
| Partial | 53 | 63.86% | 32 | 62.75% | 21 | 65.63% | ||
| Progressing | 14 | 16.87% | 8 | 15.69% | 6 | 18.75% | ||
| No response | 5 | 6.02% | 3 | 5.88% | 2 | 6.25% | ||
| NA | 7 | 8.43% | 5 | 9.80% | 2 | 6.25% | ||
| Pathological T Stage | T0 | 9 | 6.04% | 6 | 6.38% | 3 | 5.45% | 0.668 |
| T1 | 50 | 33.56% | 28 | 29.79% | 22 | 40.00% | ||
| T2 | 28 | 18.79% | 18 | 19.15% | 10 | 18.18% | ||
| T3 & T4 | 59 | 39.60% | 42 | 44.68% | 17 | 23.64% | ||
| Tis | 2 | 1.34% | 0 | 0.00% | 2 | 1.82% | ||
| Tx | 1 | 0.67% | 0 | 0.00% | 1 | 1.82% | ||
| Pathological N Stage | N0 | 73 | 48.99% | 50 | 53.19% | 23 | 40.00% | 0.17 |
| N1 | 32 | 21.48% | 22 | 23.40% | 10 | 18.18% | ||
| N2 | 32 | 21.48% | 14 | 14.89% | 18 | 20.00% | ||
| Nx | 12 | 8.05% | 8 | 8.51% | 4 | 7.27% | ||
| For NACT group - Pathological Complete Response (pCR) | Non-pCR | 74.0 | 89.2% | 46.0 | 90.2% | 28.0 | 87.5% | 0.7 |
| pCR | 9.0 | 10.8% | 5.0 | 9.8% | 4.0 | 12.5% | ||
| Surgery Type | Breast Conservative surgery | 68 | 45.64% | 44 | 46.81% | 24 | 43.64% | 0.6 |
| Mastectomy with or without Reconstruction | 81 | 54.36% | 50 | 53.19% | 31 | 40.00% | ||
| Adjuvant CTx | No | 68 | 45.64% | 46 | 48.94% | 22 | 40.00% | 0.223 |
| Yes | 81 | 54.36% | 48 | 51.06% | 33 | 60.00% | ||
| Radiotherapy treatment | No | 46 | 30.87% | 31 | 32.98% | 15 | 40.00% | 0.467 |
| Yes | 103 | 69.13% | 63 | 67.02% | 40 | 60.00% | ||
| Non-surgical Treatment | Chemotherapy alone | 46 | 30.87% | 31 | 32.98% | 15 | 27.27% | 0.607 |
| Radiotherapy alone | 7 | 4.70% | 5 | 5.32% | 2 | 3.64% | ||
| Chemoradiotherapy | 96 | 64.43% | 58 | 61.70% | 38 | 69.09% | ||
*, p-value for mean age and BMI was calculated by t-test and all the other p-values were calculated by χ2 test.